Novartis given green light for infant anti-malaria drug

Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing between two and five kilos. +Get the most important news from Switzerland in your inbox This is a significant step in global efforts to improve access to life-saving treatments for vulnerable populations, Swissmedic wrote in a statement today. The product fills a serious treatment gap for one of the most vulnerable patient groups. + Switzerland's global role in fighting malaria The availability of a treatment specifically designed for girls and young children marks an important step forward in the global fight against malaria. The approval process for the product - also known as Riamet Baby in some countries - involved close collaboration with the national regulatory authorities of eight African countries: Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Uganda and Tanzania. The Global Malaria Programme of the World Health Organisation (WHO) also ... Full story here Are you the author? Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: Featured,newsletter